Bayer flip flops amid Roundup settlement claims

9 August 2019

A report claiming that Bayer (BAYN: DE) was proposing a multi-billion dollar settlement of its US lawsuits over the alleged-cancer causing properties of Roundup (glyphosate) herbicide led the company’s shares to jump as high as 8% at one point on Friday.

Bloomberg cited ‘people familiar with the negotiations’ as saying that the German life sciences group would pay up to $8 billion to settle claims from around 18,400 claimants, with Friday morning’s report admitting that the agreement might be months away.

This share rise was welcome, as during the 14-month period since Bayer’s $63 billion acquisition of Monsanto, the company’s market value has dropped by more than a third, largely due to the Roundup lawsuits.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK